ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00977561

Public ClinicalTrials.gov record NCT00977561. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer

Study identification

NCT ID
NCT00977561
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
9 participants

Conditions and interventions

Interventions

  • Cisplatin (Or Carboplatin) Drug
  • Etoposide Drug
  • figitumumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2010
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011
Last update posted
Feb 24, 2013

2010 – 2011

United States locations

U.S. sites
34
U.S. states
9
U.S. cities
31
Facility City State ZIP Site status
Pfizer Investigational Site Washington D.C. District of Columbia 20007-2197
Pfizer Investigational Site Washington D.C. District of Columbia 20007
Pfizer Investigational Site Marrero Louisiana 70072
Pfizer Investigational Site Metairie Louisiana 70006
Pfizer Investigational Site City of Saint Peters Missouri 63376
Pfizer Investigational Site Creve Coeur Missouri 63141
Pfizer Investigational Site St Louis Missouri 63110-1094
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site Morristown New Jersey 07962
Pfizer Investigational Site Hickory North Carolina 28602
Pfizer Investigational Site Kernersville North Carolina 27284
Pfizer Investigational Site Lenoir North Carolina 28645
Pfizer Investigational Site Lexington North Carolina 27295
Pfizer Investigational Site Mount Airy North Carolina 27030
Pfizer Investigational Site North Wilkesboro North Carolina 28659
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Beaverton Oregon 97006
Pfizer Investigational Site Gresham Oregon 97030
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Portland Oregon 97239
Pfizer Investigational Site Tualatin Oregon 97062
Pfizer Investigational Site West Reading Pennsylvania 19611
Pfizer Investigational Site Christiansburg Virginia 24074
Pfizer Investigational Site Low Moor Virginia 24457
Pfizer Investigational Site Roanoke Virginia 24014
Pfizer Investigational Site Salem Virginia 24153
Pfizer Investigational Site Wytheville Virginia 24382
Pfizer Investigational Site Everett Washington 98201
Pfizer Investigational Site Federal Way Washington 98003
Pfizer Investigational Site Gig Harbor Washington 98332
Pfizer Investigational Site Kennewick Washington 99336
Pfizer Investigational Site Lakewood Washington 98499
Pfizer Investigational Site Puyallup Washington 98372
Pfizer Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00977561, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 24, 2013 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00977561 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →